Trial Profile
CS-801 phase 3 comparative study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2017
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 16 Jun 2016 New trial record